2009 Biopharma Deals Of The Year: Roche/Genentech, Movetis' IPO, Elan/J&J
This article was originally published in The Pink Sheet Daily
Executive Summary
Competition run by the IN VIVO Blog finds the most voter interest in the M&A/Alliances category, where Elan and J&J's Alzheimer's deal got the top prize.
You may also be interested in...
China Leads Pharmaceutical Growth In 2009: Asia Pharma R&D Leaders
SHANGHAI - While China's most influential meeting - the eleventh National People's Congress of China - prepares to open its third session in Beijng March 5, pharma R&D leaders gathered in Shanghai to discuss the future of the pharmaceutical industry
Start-Up Quarterly Statistics, Q4 2009
Highlights from the Q4 2009 review of start-up dealmaking: Fundraising in the biopharma, medical device, and in vitro diagnostics industries totaled $976 million, an 88% increase from the previous quarter, and a 77% jump from Q4 2008's $551 million. Of the total fundraising, 66% or $640 million went to the biopharma industry. Compared with Q3 2009, device fundraising rose by 85% (from $113 million to $209 million) and diagnostics companies raised 72% more (from $74 million to $127 million). The fourth quarter of 2009 saw eight acquisitions, all of them in the biopharma industry. Big Pharmas were busy signing deals with start-ups--Sanofi-Aventis inked three while Roche and Novartis AG each signed two.
Financings Of The Fortnight: Movetis Files First European Biopharma IPO Since Early 2008
Notable biotech financings in November also include ThromboGenics, NicOx: 4SC AG, and Fate Therapeutics.